期刊文献+

雷利度胺治疗自体造血干细胞移植后复发套细胞淋巴瘤一例并文献复习 被引量:2

Lenalidomide for the patient with mantle cell lymphoma who relapsed after autologous hematopoietic stem cell transplantation: a case report and review of the literature
原文传递
导出
摘要 目的评价雷利度胺对自体造血干细胞移植(AHSCT)后复发难治性套细胞淋巴瘤的疗效。方法回顾性分析浙江中医药大学附属第一医院血液科收治的1例行AHSCT后2次复发套细胞淋巴瘤患者的临床资料和治疗经过。先后应用雷利度胺联合地塞米松以及雷利度胺联合COD方案(环磷酰胺、长春瑞滨和地塞米松)治疗,并结合文献进行分析讨论。结果患者经以雷利度胺为主方案治疗后,疾病再次获得完全缓解,截至2015年11月初已经随访6个月,疾病未见复发。结论雷利度胺对复发难治性套细胞淋巴瘤有良好的治疗效果,可以作为AHSCT后复发套细胞淋巴瘤患者有效的治疗手段。 Objective To evaluate the efficiency of Lenalidomide in relapsed/refractory mantle cell lymphoma. Methods A retrospective study was performed on 1 patient with relapsed mantle cell lymphoma after autologous hematopoietic stem cell transplantation (AHSCT). The patient was successively treated with Lenalidomide in combination with dexamcthasone and COD (cyclophosphamide, vinorelbine and dexamethasone) respectively, and then discussed with literature. Results The patient achieved complete remission after Lenalidomide-hased therapy, and now has been followed up for 6 months, and no recurrence of disease was found. Conclusions Lenalidomide has a good therapeutic effect for the relapsed/refractory mantle cell lymphoma, which can serve as an effective mean for relapsed mantle cell lymphoma after AHSCT.
出处 《中华移植杂志(电子版)》 CAS 2016年第1期33-36,共4页 Chinese Journal of Transplantation(Electronic Edition)
基金 浙江省高校中青年学科带头人资助计划(GK2011 2012)
关键词 雷利度胺 自体造血干细胞移植 套细胞淋巴瘤 Lenalidomide Autologous hematopoietic stem cell transplantation Mantle cell lymphoma
  • 相关文献

参考文献2

二级参考文献43

  • 1Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based on its immunopathogenesis [ J ]. J Clin Neurol, 2011,7 (4) : 173-183.
  • 2Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study [J]. Ther Adv Neurol Disord, 2011,4(5) :259-266.
  • 3Strober J, Cowan MJ, Horn BN. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis [ J ]. Arch Neurol, 2009,66(5) :659-661.
  • 4Daikeler T, Tichelli A, Passweg J. Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases[ J]. J Pediatr Res, 2012,71 (4 Pt 2) :439-444.
  • 5Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases [ J ]. Haematologica, 2010,95 (2) :284-292.
  • 6Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases [ J ]. Hematology Am Soc Hematol Educ Program 2011,2011:280-284.
  • 7Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmuue disease: a retrospective study of the EBMT Autoimmune Disease Working Party [J]. Blood, 2011,118(6) :1693-1698.
  • 8Shah Sr,Tran Tm.Lenalidomide in myelodysplastic syndrome and multiple myeloma[J].Drug,2007,67(13):1869-1881.
  • 9Dregde K,Horsfall R,Robinson SP,et al.Orally administered lenalidomide(CC-5013)is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro[J].Microvasc Res,2005,69(1-2):56-63.
  • 10Kotal V,Goel S,Nischal S,et al.Mechanisms of action of lenalidomide in hematological malignancies[J].J Hematol Oncol,2009,2(36):1-10.

共引文献3

同被引文献28

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部